Brief: Corbus Pharmaceuticals Announces First Patient Dosed With Its Nectin-4 Targeting ADC CRB-701
25/06/2025 13:22
June 25 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O: CORBUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED WITH ITS NECTIN-4 TARGETING ADC CRB-701 IN COMBINATION WITH PEMBROLIZUMAB CORBUS PHARMACEUTICALS HOLDINGS: EXPECTS TO PROVIDE DATA UPDATE & ESTABLISH RECOMMENDED PHASE 2 DOSE IN Q4 THIS YEAR Source text: ID:nGNX1dNvvr Further company coverage: CRBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study